DVA vs OMCL: fair value comparison
DaVita Inc. and Omnicell, Inc. · Updated 2026-09-12
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, DVA currently sits closer to the top of our discount ranking. OMCL carries the stronger quality grade.
| DVA | OMCL | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $181.55 | $34.51 |
| 12-month range | $111.19–$240.09 | $29.96–$48.70 |
| Sector rank | #40 of 113 Healthcare | #42 of 113 Healthcare |
| Quality grade | C | A |
| Leverage | Low | Low |
| Margin trend | Contracting | Stable |
| Revenue growth | Modest | Modest |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | — | Downtrend |
| DCF cross-check | Undervalued | Undervalued |
| 52-week position | The upper-middle quarter | The bottom quarter |
Full single-stock breakdowns: DVA fair value analysis · OMCL fair value analysis